Health-Illness Transition Experiences Among Patients with Pancreatic Cancer

Outcomes 1. Describe the most common health-illness transitions experienced by patients with pancreatic cancer 2. Describe the relationship between management of health-illness transitions and psychological distress Original Research Background Health-illness transitions (HITs) include care transitions (changes in cancer status, treatment, or goals of care) and personal transitions (physical, emotional, social, or spiritual changes). Management of HITs is an important self-management skill because unmanaged HITs can increase distress. HITs experienced during pancreatic cancer have not been previously described, and patients with pancreatic cancer may have an abbreviated opportunity to learn self-management of HITs. Research Objectives To elucidate how patients with pancreatic cancer experience and manage HITs and whether HITs are associated with distress. Methods We enrolled patients with pancreatic cancer undergoing chemotherapy at Memorial Sloan Kettering Cancer Center. We assessed extent and management of HITs via the Measurement of Transitions in Cancer Scale and evaluated psychological distress via the Distress Thermometer (DT). Open-ended questions explored transitions not captured by the existing scale and the influence of COVID-19 on experience and management of HITs. Descriptive statistics were used to summarize demographic and clinical characteristics, HIT variables, and distress scores. We calculated Spearman's correlations between distress and unmanaged transitions and used thematic analysis for examination of qualitative data. Results Among 55 participants (median age = 70;98% pancreatic adenocarcinoma;median time since diagnosis = 4 months), all experienced at least 1 HIT and managed transitions moderately well. Physical (95%) and emotional (93%) transitions were most common. Unmanaged transitions and distress were correlated;severely distressed participants (7-10 on the DT) reported more HITs and worse management. Participants suggested new transition types: financial and caregiver. COVID-19 increased distress and complicated transition management. Participants reported that HITs made self-management more difficult and identified facilitators and barriers. Conclusion Patients with pancreatic cancer experience multiple HITs, which, when unmanaged, are associated with distress. Implications for Research, Policy, or Practice Findings about HITs can inform interventions targeting self-management skill building to alleviate distress and improve quality of life among patients with pancreatic cancer. Because HITs may vary for patients with different cancers, cancer-specific examination and intervention development will be needed.

The COVID-19 Pandemic Upended Youth Sports.

The American Academy of Pediatrics estimates that approximately 35 to 45 million young people age 6 to 18 years participate in some type of athletics every year. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic interrupted youth sports and left many children unable to train in-person with teammates and coaches. Given the large impact sports and physical activity have on the lives of children and adolescents, the effect that coronavirus disease 2019 restrictions have had on the psychological and physical well-being of young athletes is significant. The youth sports community has worked hard to find creative ways to safely bring children and adolescents back to the fields and courts with rules and regulations in place. Youth practices and competitions are potential spreader events for SARS-CoV-2, especially given the challenge of identifying young athletes and other participants with asymptomatic active viral infection. With the implementation of rapid result testing programs and the US Food and Drug Administration approval of a highly effective vaccine in adolescents and, most recently, in younger children, youth sports are once again becoming a place for young athletes to train, socialize, and learn invaluable lessons in teamwork and leadership. [Pediatr Ann. 2021;50(11):e450-e453.].

Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.

As a result of the COVID-19 pandemic, most centers performing allogeneic hematopoietic cell transplantation (allo-HCT) have switched to the use of cryopreserved grafts. Previous investigators have suggested that cryopreserved allografts may heighten risk of nonengraftment. To date, no study has investigated the effect of cryopreservation of CD34-selected hematopoietic progenitor cells (CD34+ HPCs) used as the sole graft source. In this study, we sought to evaluate outcomes after unrelated donor or matched sibling allo-HCT with cryopreserved CD34+ HPCs. This was a single-center analysis of adult patients with hematologic malignancies who underwent allo-HCT with cryopreserved CD34-selected allo-HCT grafts between January 2010 and June 2017. All patients received ablative conditioning and antirejection prophylaxis with rabbit antithymocyte globulin. G-CSF-mobilized leukapheresis products underwent CD34 selection using the CliniMACS Reagent System. Cells were then cryopreserved in DMSO (final concentration 7.5%) to -90 °C using a controlled-rate freezing system before being transferred to vapor-phase liquid nitrogen storage. In internal validation, this method has shown 92% mean CD34+ cell viability and 99.7% mean CD34+ cell recovery. Engraftment was defined as the first of 3 consecutive days of an absolute neutrophil count of ≥0.5. Platelet recovery was recorded as the first of 7 consecutive days with a platelet count ≥20 K/µL without transfusion. Kaplan-Meier methodology was used to estimate overall survival (OS) and relapse-free survival (RFS), and cumulative incidence functions were used to estimate rates of relapse, nonrelapse mortality (NRM), and acute graft-versus-host disease (GVHD). A total of 64 patients received a cryopreserved CD34-selected graft. The median CD34+ cell count before cryopreservation was 6.6 × 106/kg (range, 1.4 to 16.1 × 106/kg), and the median CD3+ cell count was 2.0 × 103/kg (range, 0 to 21.1 × 106/kg). All patients were engrafted, at a median of 11 days post-HCT (range, 8 to 14 days). One patient had poor graft function in the setting of cytomegalovirus viremia, necessitating a CD34-selected boost on day +57. The median time to platelet recovery was 16 days (range, 13 to 99 days). The estimated 2-year OS was 70% (95% confidence interval [CI], 58% to 83%) with cryopreserved grafts versus 62% (95% CI, 57% to 67%) with fresh grafts (hazard ratio [HR], 0.86; 95% CI, 0.54 to 1.35; P = .5). The estimated 2-year RFS in the 2 groups was 59% (95% CI, 48% to 74%) versus 56% (95% CI, 51% to 61%; HR, 1.01; 95% CI, 0.68 to 1.51; P > .9). The cumulative incidence of relapse at 2 years was 29% (95% CI, 17% to 41%) versus 23% (95% CI, 19% to 27%; P = .16), and the cumulative incidence of NRM at 2 years was 17% (95% CI, 9% to 28%) versus 23% (95% CI, 19% to 28%; P = .24). The cumulative incidence of grade II-IV acute GVHD by day +100 was 16% with cryopreserved grafts (95% CI, 8% to 26%) and 16% (95% CI, 13% to 20%; P = .97) with fresh grafts. Moderate to severe chronic GVHD by day +365 occurred in only 1 recipient of a cryopreserved graft (2%). Our data show that in patients with hematologic malignancies who received cryopreserved allogeneic CD34+ HPCs, engraftment, GVHD, and survival outcomes were consistent with those seen in recipients of fresh allogeneic CD34+ HPC grafts at our center. Our laboratory validation and clinical experience demonstrate the safety of our cryopreservation procedure for CD34-selected allografts.

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development.

Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts.